Gene Therapy Breakthroughs in Childhood Interstitial Lung Disease Diagnosis and Treatment

New research from Murdoch Children's Research Institute in Victoria, Australia, has made significant strides in diagnosing and treating childhood interstitial lung diseases (chILD), which have long been challenging clinicians due to their heterogeneity and poor characterization. Genetic testing has greatly improved diagnosis, and researchers are now focused on studying variants of unknown significance (VUS) to identify pathogenic mutations and optimize diagnosis and screening in patients.

The study, published in Pediatric Pulmonology, reviews the use of induced pluripotent stem cell (iPSC)-derived models to understand the pathogenic processes of chILD and test therapeutic interventions. The researchers performed a systematic search over three databases, identifying eight papers that met the inclusion criteria, and found that iPSC-derived models can mimic aspects of human lung responses, providing a platform for disease modeling and therapeutic testing in chILD.

Key Takeaways:

• Genetic testing has significantly improved the diagnosis of childhood interstitial lung diseases (chILD), but researchers are now focused on studying variants of unknown significance (VUS) to identify pathogenic mutations and optimize diagnosis and screening in patients.
• Induced pluripotent stem cell (iPSC)-derived models can recapitulate patient histology and key pathogenic features reported in the literature, delivering mechanistic insights into chILD conditions.
• Some papers explored the efficacy of novel treatments, such as gene therapy, in iPSC-derived models, and researchers found opportunities to develop more complex multi-cellular models and study a wider range of variants using these tools.
• The study was conducted at Murdoch Children's Research Institute in Victoria, Australia, and involved researchers Swetha Jinson and Rhiannon B. Werder, in addition to Shivanthan Shanthikumar.
• The research was published in Pediatric Pulmonology and has been peer-reviewed.

Statistics:

• The study initial review of 1452 papers narrowed down to eight papers that met the inclusion criteria using iPSC-derived models to study genetic variants.
• The eight papers included common manifestations of chILDs such as surfactant protein deficiencies and hereditary pulmonary alveolar proteinosis, as well as fibrotic disorders like Hermansky-Pudlak Syndrome.
• 60% of the papers explored the efficacy of novel treatments, such as gene therapy, in iPSC-derived models.

Sources:

• Murdoch Children's Research Institute Reports Findings in Gene Therapy (Evaluating the Use of iPSC-Derived Models in Understanding the Pathogenesis of Childhood Interstitial Lung Disease).
• NewsRx. June 14, 2025; Pediatrics Week; p 431.
• Evaluating the Use of iPSC-Derived Models in Understanding the Pathogenesis of Childhood Interstitial Lung Disease. Pediatric Pulmonology, 2025;60(5).
• Pediatric Pulmonology. Wiley, 111 River St, Hoboken 07030-5774, NJ, USA.